US-based ophthalmology company Santen and biopharmaceutical company twoXAR have entered a strategic research collaboration to identify new drug candidates for glaucoma.

Glaucoma is a group of degenerative disorders of the optic nerve that causes blindness.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Under the agreement, twoXAR will discover, screen, and prioritise novel drug candidates using its computational drug discovery platform for application in occular indications, with a specific focus on glaucoma.

Santen will have the exclusive right to develop and commercialise drug candidates arising from the collaboration.

Santen global research and development senior corporate officer, chief scientific officer and head Naveed Shams said: “We are pleased to have established this strategic collaboration with twoXAR, which aims to deliver new treatment options for the millions of people living with glaucoma globally.

“This collaboration is an exciting example that demonstrates how software-driven approaches can lead the discovery of new drugs rather than simply supporting existing hypotheses.”

“By leveraging twoXAR’s proprietary computational discovery platform to identify novel targets in areas of glaucoma, Santen further strengthens our R&D capabilities while expanding our pipeline of innovative therapeutic opportunities that help fulfil the unmet medical needs in ophthalmology.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

In 2010, 60.5 million people worldwide were reported to be living with glaucoma and this number is expected to increase to nearly 80 million by 2020.

twoXAR co-founder and CEO Andrew Radin said: “This collaboration is an exciting example that demonstrates how software-driven approaches can lead the discovery of new drugs rather than simply supporting existing hypotheses.

“The combination of twoXAR’s unique capabilities in artificial intelligence-driven drug discovery, along with Santen’s experience in ophthalmic product development and commercialisation, provides a foundation upon which we can rapidly discover and develop new therapeutic candidates to treat glaucoma and bring better treatment options to the millions of people living with this disease.”